Proton Therapy Fails to Beat IMRT in Prostate Cancer

Published Date: 08 Jun 2026

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Read Full News

Latest News

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Women with breast cancer show interest in self-injecting their medication.

News All Time

Sequencing Method Flags AML Relapse Risk Around Transplant

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Does Maintenance Therapy Extend Life in mCRC?

Maintenance therapy is linked to longer overall survival after first-line bevacizumab-based combination chemotherapy in patients with metastatic colorectal cancer, a study finds.

Preschoolers With Cancer Have Poor Motor Skills

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

Industry trials focus on single drugs, while publicly funded trials often look at broader cancer care. It’s a ‘complementary’ approach, but pharma enrolls over 90% of patients.

Ruxolitinib Reduces Acute GVHD in Transplant Patients

A phase 3 trial evaluates a low-dose ruxolitinib-based regimen for graft-vs-host disease prophylaxis among patients undergoing haploidentical hematopoietic stem-cell transplantation.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Recommended News For You

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Combination therapy improves outcomes for advanced triple-negative breast cancer

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

An Intimate Life of Medical Innovation and Charity.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

Recommended Articles For You

Rehabilitation of Hand Dexterity Following Hematologic Treatment-Associated Deconditioning 

Bone-on-a-Chip Systems: A Revolutionary Approach to Modeling Hematological Cancers 

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice 

From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women

1.

Tumor Ecosystem Rewiring Through Adaptive Therapeutics

2.

Seeing the Unseen: Examining Chancroid Through Images

3.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

4.

The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology

5.

Decoding Granular Cell Tumor: What You Need to Know

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Advances in Modern Cancer Treatment

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

3.

Thromboprophylaxis In Medical Settings

4.

Navigating the Complexities of Ph Negative ALL - Part VII

5.

Managing Common Side Effects During Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot